Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT06136819
PHASE1

RT-310 Dose Escalation BPH Study

Sponsor: Resurge Therapeutics Inc.

View on ClinicalTrials.gov

Summary

RT-310, a novel implant, is intended to minimally invasive treat locally the prostate gland for the management of prostate disease, while minimizing side-effects. The objectives of the study are to assess whether RT-310 is safe and feasible for the participant population.

Official title: Safety and Feasibility Dose Escalation Study for Evaluation of RT-310 for Treatment of Lower Urinary Tract Symptoms (LUTS) Secondary to Benign Prostatic Hyperplasia (BPH)

Key Details

Gender

MALE

Age Range

50 Years - 80 Years

Study Type

INTERVENTIONAL

Enrollment

20

Start Date

2024-04-19

Completion Date

2027-12

Last Updated

2025-11-28

Healthy Volunteers

No

Interventions

COMBINATION_PRODUCT

RT-310

Combination Product: RT-310 Implant for Investigational Treatment of Lower Urinary Tract Symptoms Secondary to BPH (Benign Prostatic Hyperplasia)

Locations (4)

Australian Clinical Trials

Wahroonga, New South Wales, Australia

Goldfields Urology

Bendigo, Victoria, Australia

Western Urology

Maribyrnong, Victoria, Australia

Tauranga Urology Research

Tauranga, North Island, New Zealand